News

How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

Cristina Puig Saus, PhD, who led the work, and co-authors Antoni Ribas, PhD, and Jim Heath, PhD, sat down to discuss the work and its future implications. You can watch that video here, or by playing the video at the top of this page.

For more information about the Nature paper, you can read the UCLA Health story here.

 

Recent Articles

  • Common Immune Response Protective Across Many Diseases

    Combined, infection, autoimmunity and cancer account for 40 percent of deaths worldwide and represent major global health challenges. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases. Their findings offer promising avenues for exploring multi-disease therapeutic strategies.

  • Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

    In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.

  • ISB Building at dusk

    2023 Year in Review

    Throughout 2023, ISB research has been published in impactful peer-reviewed journals and our scientists have been featured in major media outlets and popular podcasts. In this 2023 Year in Review, we showcase some of our most important and interesting highlights of the year.